TEM, CTX-M, SHV Genes in ESBL-Producing Escherichia coli and Klebsiella pneumoniae Isolated from Clinical Samples in a County Clinical Emergency Hospital Romania-Predominance of CTX-M-15

Alice Elena Ghenea 1,†, Ovidiu Mircea Zlatian 1,†, Oana Mariana Cristea 1,*, Anca Ungureanu 1, Radu Razvan Mititelu 1, Andrei Theodor Balasoiu 2,†, Corina Maria Vasile 3,*, Alex-Ioan Salan 4, Daniel Iliuta 5, Mihaela Popescu 6, Anca-Loredana Udriștoiu 7 and Maria Balasoiu 1

1 Department of Bacteriology-Virology-Parasitology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; gaman_alice@yahoo.com (A.E.G.); ovidiu.zlatian@gmail.com (O.M.Z.); ancaungureanu65@yahoo.com (A.U.); mradurazvan@gmail.com (R.R.M.); balasoiu.maria@yahoo.com (M.B.)
2 Department of Ophthalmology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; andrei_theo@yahoo.com
3 Department of Paediatrics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
4 Department of Oral and Maxillofacial Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; alex.salan@umfc.ro
5 Department of Psychiatry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; iliatudaniel94@gmail.com
6 Department of Endocrinology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; mihaela.n.popescu99@gmail.com
7 Faculty of Automation, Computers and Electronics, University of Craiova, 200776 Craiova, Romania; anca.udristoiu@edu.ucv.ro
* Correspondence: ioneteoana@yahoo.com (O.M.C.); corina.vasile93@gmail.com (C.M.V.)
† These authors contributed equally to this work.

Abstract: Background: CTX-M betalactamases have shown a rapid spread in the recent years among Enterobacteriaceae and have become the most prevalent Extended Spectrum Beta-Lactamases (ESBLs) in many parts of the world. The introduction and dissemination of antibiotic-resistant genes limits options for treatment, increases mortality and morbidity in patients, and leads to longer hospitalization and expensive costs. We aimed to identify the beta-lactamases circulating encoded by the genes blaCTX-M-15, blaSHV-1 and blaTEM-1 in Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) strains. Furthermore, we established the associated resistance phenotypes among patients hospitalized in the Intensive Care Unit (ICU) from County Clinical Emergency Hospital of Craiova, Romania. Methods: A total of 46 non-duplicated bacterial strains (14 strains of E. coli and 32 strains of K. pneumoniae), which were resistant to ceftazidime (CAZ) and cefotaxime (CTX) by Kirby–Bauer disk diffusion method, were identified using the automated VITEK2 system. Detection of ESBL-encoding genes and other resistance genes was carried out by PCR. Results. E. coli strains were resistant to 3rd generation cephalosporins and moderately resistant to quinolones, whereas K. pneumoniae strains were resistant to penicillins, cephalosporins, and sulfamides, and moderately resistant to quinolones and carbapenems. Most E. coli strains harbored blaCTX-M-15 gene (13/14 strains), a single strain had the blaSHV-1 gene, but 11 strains harbored blaTEM-1 gene. The mcr-1 gene was not detected. We detected tet(A) gene in six strains and tet(B) in one strain. In K. pneumoniae strains we detected blaCTX-M-15 in 23 strains, blaSHV-1 in all strains and blaTEM-1 in 14 strains. The colistin resistance gene mcr-1 was not detected. The tetracycline gene tet(A) was detected in 11 strains, but the gene tet(B) was not detected in any strains. Conclusions. The development in antibiotic resistance highlights the importance of establishing policies to reduce antibiotic use and improving the national resistance surveillance system in order to create local antibiotic therapy guidelines.

Keywords: antimicrobial resistance; Klebsiella pneumoniae; Escherichia coli; CTX-M-15; ESBL; antibiotic resistance
1. Introduction

Enterobacteria-producing extended-spectrum beta-lactamases (ESBL) play an important role in increasing hospitalization time, healthcare infections, mortality, and morbidity rates. [1]. *Escherichia coli* (*E. coli*) is a commensal of the intestinal flora, but may be involved in diseases such as septicemia, urinary tract infections, or purulent infections, in which the capacity to acquire antibiotic resistance genes is obviously increased [2,3]. *Klebsiella pneumoniae* (*K. pneumoniae*) can also be found in the intestinal flora, being an opportunistic pathogen involved in the production of nosocomial infections, especially in immunocompromised patients and hospitalized in the intensive care unit. This pathogen can also acquire resistance genes to different classes of antibiotics, which underlie the increased pathogen potential and the appearance of severe forms of the disease [2,4–6].

The most common mechanism of beta-lactam antibiotic resistance is beta-lactamase production. Due to extended-spectrum beta-lactamases (ESBLs), this phenomenon of resistance has increased in medical practice [7–10]. They are plasmid-encoded enzymes with the ability to hydrolyze bonds of β-lactam rings from antibiotics like penicillins, cephalosporins, and aztreonam, and are inhibited by the action of clavulanic acid [8,9]. Due to the coexistence of different modifying enzymes on the same plasmid, there is a possibility of resistance to other classes of antibiotics, such as fluoroquinolones, aminoglycosides, tetracyclines, and trimethoprim sulfamethoxazole [11,12].

In various studies, the most investigated types are TEM, SHV, OXA, and CTX-M of these, CTX-M being the most frequently associated with resistance to these antibiotics [10–12]. There are more than 130 different types of CTX-M enzymes divided into five different groups as follows: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25 [13]. Of these, the most common type in hospitals and in the community is the CTX-M-15 type [13]. Currently, more than 140 different types of TEM type beta-lactamases are known, TEM-1 being most encountered in *E. coli* and *K. pneumoniae*. There are also more than 100 different types of SHV, especially existent in *Pseudomonas aeruginosa* and *Acinetobacter* spp. [14].

The emergence and spread of these antibiotic-resistant genes reduce the chances of treatment, and increase the mortality and morbidity of patients with prolonged hospitalization and high costs [15]. Therefore, it is necessary to identify them as soon as possible and apply measures to reduce the prevalence of ESBLs. It is a priority to treat patients with effective antimicrobials, to maintain proper hygiene rules, and to try as far as possible to avoid certain invasive procedures, such as central venous catheterization [14].

For detection of multidrug-resistance, often the conventional antimicrobial testing is not sufficient [16]. Often, microorganisms are not identified as ESBL producers and so they can spread in the hospital environment [17] so the identification of resistant phenotypes is crucial, especially in countries with excessive use of antibiotics and deficient infection control measures [18,19].

The main objective of this work was to establish the beta-lactamases circulating in the Oltenia region of Romania, encoded by the genes *blaCTX-M-15*, *blaSHV-1*, and *blaTEM-1* in *E. coli* and *K. pneumoniae* strains and also the associated resistance phenotypes among patients from the County Clinical Emergency Hospital of Craiova, Romania.

2. Material and Methods

2.1. Bacterial Strains

We collected 46 non-duplicated bacterial strains (14 strains of *E. coli* and 32 strains of *K. pneumoniae*), which were resistant to ceftazidime (CAZ) and cefotaxime (CTX) by the diffusimetric Kirby–Bauer method, from patients hospitalized in the Intensive Care Unit (ICU) of County Clinical Emergency Hospital of Craiova, Romania, which serves patients from the entire Oltenia region, between 1 January 2020–31 December 2021. Strains were obtained from purulent secretions, catheters, peritoneal fluids, tracheal aspirates, and sputum.
2.2. Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing was accomplished by Kirby–Bauer disk diffusion method, for ceftazidime (30 µg) and cefotaxime (30 µg), according to the standard Clinical Laboratory Standards Institute (CLSI, 2019) [20]. *E. coli* and *K. pneumoniae* strains that were resistant to both antibiotics were tested using the automated VITEK2 system (Biomerieux, Marcy-l’Étoile, France) against amikacin, ampicillin, aztreonam, cefazolin, cefepime, ceftriaxone, ciprofloxacin, tetracycline, gentamycin, tobramycin, moxifloxacin, norfloxacin, piperacillin/tazobactam, sulphamethoxazole/trimethoprim, tigecycline, tobramycin, imipenem, meropenem, and ertapenem. The internal quality control for Muller-Hinton agar and antibiotic disks was performed using control strains *E. coli* ATCC 25922, *E. coli* (BAA-197) and *K. pneumoniae* (ATCC 51503, ATCC 700603).

The confirmation of ESBL production was carried out phenotypically using a double-disk synergy test [20] with kits from ROSCO (Taastrup, Denmark).

A strain was classified as multidrug-resistant (MDR) if it was resistant to at least one agent in three or more antimicrobial classes [21].

2.3. Molecular Testing

Genomic DNA was extracted from *E. coli* and *K. pneumoniae* strains as follows. Colonies were suspended in 184 mL tube with sterile water and we added 16 mL proteinase K (15 mg/mL). The mixture was incubated for 30 min at 56 °C. Automated DNA extraction was then performed using Maxwell® 16 System (Promega, Madison, WI, USA) instrument with the extraction kit Maxwell® 16 Cell DNA Purification Kit (Promega, USA) that is suitable for both eukaryotic and prokaryotic DNA extraction.

The extended spectrum beta-lactamase genes (*bla*<sub>CTX-M-15</sub>, *bla*<sub>SHV-1</sub> and *bla*<sub>TEM-1</sub>) were detected through in-house PCR using consensus primers and methodology according to those described by Monstein et al. [22]. The multiplex PCR assay was carried out using GoTaq® Polymerase and dNTP Mix from Promega manufacturer on an Eppendorf MasterCycler® thermal cycler. The primers for *bla*<sub>CTX</sub>/*bla*<sub>SHV</sub>/*bla*<sub>TEM</sub> genes were ordered from Invitrogen—“Class A extended beta-lactamase primers”. Electrophoretic separation of resulted amplicons was done using ethidium bromide-stained 1% agarose gel from Sigma Aldrich. We also screened the strains for the presence of the *mcr-1* gene [23] and the *tet(A)/tet(B)* genes [24] using single PCR assay with similar parameters to those of Adelowo and Fagade [24]. Amplicon detection and evaluation from agarose gels for each of the techniques we employed was done on a G:Box Chemi HR (Syngene) Bio Imaging system. Standard *E. coli* (BAA-197) and *K. pneumoniae* (ATCC 51503, ATCC 700603) strains producing ESBLs, as well as DNA from previous extractions from known enzymes producing strains were used as controls.

2.4. Statistical Analysis

The data collected from the informatic system for all microbiology samples were introduced on a weekly basis into the software STATA (StataCorp LLC, TX, USA), which calculated the resistance profile and the classification in MDR or non-MDR criteria according to ECDC guidelines algorithm [21], in order to select the strains to be included in the study. We also used the software to generate the tables and figures presented in this study.

3. Results

All the strains being studied fulfilled the criteria for MDR [21] and were positive for phenotypic ESBL test.

3.1. Antibiotic Resistance in *E. coli*

All 14 strains of *E. coli* were resistant to ampicillin, cefazolin, ceftazidime, ceftriaxone, and cefuroxime as in Figure 1.
3.1. Antibiotic Resistance in E. coli
All 14 strains of E. coli were resistant to ampicillin, cefazolin, ceftazidime, ceftriaxone, and cefotaxime. Twenty-six strains were resistant to ceftriaxone and cefepime (81.25%). From the carbapenem group 20 strains were resistant to imipenem (62.50%), 16 to ertapenem (50.00%), and 14 to meropenem (43.75%). Besides beta-lactam antibiotics, 14 strains were resistant to gentamicin and tetracycline, 12 to tigecycline, 16 to piperacillin/tazobactam (50.00%), and 24 to sulfamethoxazole/trimethoprim (75.00%). The resistance rates under 30% were observed for amikacin, tigecycline, and meropenem (81.25%). From the carbapenem group 20 strains were resistant to imipenem (62.50%), 16 to ertapenem (50.00%), and 14 to meropenem (43.75%). Besides beta-lactam antibiotics, 14 strains were resistant to gentamicin and tetracycline, 12 to tigecycline, 16 to piperacillin/tazobactam (50.00%), and 24 to sulfamethoxazole/trimethoprim (75.00%). The A high rate of resistance was observed for cefepime \( (n = 12; 85.17\%) \) and aztreonam \( (n = 10; 71.43\%) \). Relative moderate resistance was observed for tetracycline, gentamycin, and tobramycin \( (n = 8; 57.14\%) \); moxifloxacin \( (n = 7; 50.00\%) \); ciprofloxacin \( (n = 6; 42.86\%) \); norfloxacin \( (n = 6; 42.86\%) \); and piperacillin/tazobactam \( (n = 16; 50.00\%) \). Relatively low resistance rates under 30% were observed for amikacin, tigecycline, and meropenem \( (n = 2; 14.29\%) \), and also for piperacillin/tazobactam, sulfamethoxazole/trimethoprim, imipenem, and ertapenem \( (n = 4; 28.57\%) \). All strains were susceptible to colistin.

3.2. Genetic Characteristics of Multidrug-Resistant E. coli Strains
Many of the 14 E. coli strains harbored \( \text{bla}_{\text{CTX-M-15}} \) gene (13 strains), most from purulent secretions. A single E. coli strain had the \( \text{bla}_{\text{SHV-1}} \) gene, but 11 strains harbored \( \text{bla}_{\text{TEM-1}} \) gene. The \( \text{mcr-1} \) gene was not detected. We detected \( \text{tet(A)} \) gene in six strains and \( \text{tet(B)} \) in one strain.

3.3. Antibiotic Resistance in K. pneumoniae
All 32 strains of K. pneumoniae were resistant to ampicillin, cefazolin, ceftazidime, cefuroxime, and cefotaxime. Twenty-six strains were resistant to ceftriaxone and cefepime (81.25%). From the carbapenem group 20 strains were resistant to imipenem (62.50%), 16 to ertapenem (50.00%), and 14 to meropenem (43.75%). Besides beta-lactam antibiotics, 14 strains were resistant to gentamicin and tetracycline, 12 to tigecycline, 16 to piperacillin/tazobactam (50.00%), and 24 to sulfamethoxazole/trimethoprim (75.00%).
resistance to quinolones was also important, as 22 strains were resistant to ciprofloxacin (68.75%), 12 to moxifloxacin (37.50%), and 20 to norfloxacin (62.50%). Very low resistance was recorded to amikacin (4 strains: 12.5%). All strains were susceptible to colistin (Figure 2).

**Figure 2.** Resistance of *K. pneumoniae* strains to various antibiotics. (AMP: Ampicillin; AMK: Amikacin; ATM: Aztreonam; CZO: Cephazolin; FEP: Cephepime; CAZ: Cephtazidime; CRO: Ceftriaxone; CXM: Cefuroxime; CTX: Cefotaxime; TGC: Tigecyclin; TPZ: Piperacillin/Tazobactam; MEM: Meropenem; CIP: Ciprofloxacin; SXT: Sulphametoxazole/Trimethoprim; ETP: Ertapenem; GEN: Gentamycin; MXF: Moxifloxacin; NOR: Norfloxacin; TCY: Tetracycline; TOB: Tobramycin).

3.4. Genetic Characteristics of the *K. pneumoniae* Strains

In *K. pneumoniae* strains, we detected beta-lactamase genes *bla*\textsubscript{CTX-M-15} in 23 strains, *bla*\textsubscript{SHV-1} in all strains, and *bla*\textsubscript{TEM-1} in 14 strains. The colistin resistance gene *mcr-1* was not detected. The tetracycline gene *tet*(A) was detected in 11 strains, but the gene *tet*(B) was not detected in any strains.

4. Discussion

Frequently, beta-lactam antibiotics are used as the first-line drugs in infections caused by *Enterobacteriaceae* [25]. This study investigates the ESBL-producing *Enterobacteriaceae* in a tertiary care Romanian hospital. We confirmed the spread of the gene *bla*\textsubscript{CTX-M-15} in isolates from Romania and that these strains show resistance to various antibiotic classes.

The prevalence of ESBL-producing *Enterobacteriaceae* varies greatly around the globe. In all countries, in settings where the patients are treated with antibiotics, there is a high prevalence of multidrug-resistant *Enterobacteriaceae* [26]. Low rates were reported in North America and Europe [27,28] and high rates in Asia [29], South America [30], and Africa [31]. Their spread is encouraged by antimicrobials used without a prescription, poor hygiene,
counterfeit drugs, high prevalence of infectious diseases, and lack of diagnostic tools for infections and antibiotic resistances [32,33].

The rates of resistance of Enterobacteriaceae nosocomial isolates are increasing also in Romania [34–37] as in other countries [38–42]. There are insufficient studies on the nature and prevalence of the ESBLs in nosocomial settings of Romania. In this study, we describe the prevalence and nature of the ESBLs produced by the Enterobacteriaceae circulating in a hospital from the Oltenia region of Romania.

In the ICU, patients with systemic infections are treated with a massive number of antibiotics [43]. These strains are probably transmitted through the air in healthcare settings, particularly in the ICU between patients on mechanical ventilation [44]. This transmission route is supported by the fact that 4 out of 14 E. coli strains and 8 out of the 32 Klebsiella pneumoniae strains were recovered from the samples from the respiratory tract.

The penicillin and cephalosporin resistance patterns observed in our strains can be explained by the excessive use of ceftriaxone and cefotaxime in the empirical therapy in hospitals, and hospitalization itself has been identified as a risk factor for infection with ESBL-producing Enterobacteriaceae as plasmids carrying genes that encode ESBLs can be easily transmitted horizontally between different bacteria in the hospital environment [45–47]. The study shows an association of the ESBL production with resistance to aminoglycosides (excepting amikacin), tetracycline, and trimethoprim/sulfamethoxazole, as previously reported [48–50]. The cross-resistance phenomenon is alarming because it restricts greatly the choices for empirical therapy in patients infected with ESBL-producing Enterobacteriaceae.

In our study, low resistance rates were observed to amikacin, tigecycline, and meropenem in E. coli and K. pneumoniae strains that had moderate resistance to the same antibiotics. However, meropenem should be used with caution in empirical therapy to avoid the selection of carbapenemases-producing Enterobacteriaceae and amikacin is toxic for kidneys. Nevertheless, in serious infections with ESBL-producing Enterobacteriaceae, the carbapenems are currently considered drugs of choice, for example, ertapenem once daily. Sometimes the patients show a partial response to non-carbapenem antibiotics [51,52]. Some authors suggested that amikacin can be successfully used in these infections due to the low resistance rates in Enterobacteriaceae [53].

There is a strong geographical variation in the CTX-M type of ESBLs in E. coli and K. pneumoniae isolates. The most prevalent allele with a worldwide distribution is CTX-M-15, which belongs to the CTX-M-1 group [8,38,54]. CTX-M-14 is highly prevalent in some Asian countries [55], whereas in South America predominates CTX-M-2 and CTX-M-8 [55,56]. We found the blaCTX-M-15 in more than 90% of the E. coli isolates (Table 1), a finding that resembles other studies in nosocomial settings in Portugal [57], Lithuania [58], Hungary [59], and Germany [60], where it was the most prevalent ESBL type. Recently, blaCTX-M-15 was detected in E. coli in cats and dogs [61,62], other companion animals and in poultry [63]. Similar results were reported from Spain [64]. CTX-M-15 is frequently associated with the epidemic clone ST131 with worldwide distribution [62,65,66]. In our study, the prevalence of the blaCTX-M-15 gene was detected in 13/14 strains in E. coli (Table 1) and 23/32 strains in Klebsiella pneumoniae (Table 2); this high prevalence was previously reported in samples obtained from humans [4,61,67,68] and pets in Portugal [69], Italy [70], and Germany [60]. The beta-lactamase CTX-M-15 is endemic in various countries and rapidly spreads to different Enterobacteriaceae species [14]. In European countries, a high prevalence of CTX-M-15 has been reported in many studies [58,60,61,63]. These data show a spread of blaCTX-M-15 gene in both humans and animals across Europe.
In Romania, there are a few studies on the prevalence of CTXM-15 ESBL variant in isolates from clinical settings [71–73] and in pets [63,74,75]. We had a few strains of E. coli and K. pneumoniae in which CTXM-15 gene was not detected but they were resistant to 3rd generation cephalosporins. That can be explained by the presence of other beta-lactamases, as carbapenemases (because these strains were resistant to carbapenems). Indeed, the KPC (K. pneumoniae carbapenemases) [76] and NDM (New Delhi Metallobeta-lactamases) lactamases [77] can induce resistance not only to carbapenems, but also to cephalosporins.

The \textit{bla}\textit{SHV-1} gene was detected in our study in only one E. coli strain from 14 studied, but in all K. pneumoniae strains, in accordance with other authors, who found it sometimes in association with \textit{ctx} genes, in both animals and humans [6,62]. The ESBLs SHV have also been detected in animal wildlife [78–80].

### Table 1. Resistance phenotype and associated genotype in the 14 \textit{E. coli} strains from clinical samples in a Romanian hospital.

| No. | Origin            | Resistance Phenotype | Beta-Lactamases                      | \textit{tet} Genes |
|-----|-------------------|----------------------|--------------------------------------|-------------------|
| 1   | Purulent secretion| AMP ATM CZO FEP CAZ CRB CRO CXM CTX | CTX-M-15 TEM-1 | ND                |
| 2   | Purulent secretion| AMP ATM CZO FEP CAZ CRB CRO CXM CTX GEN TGY | CTX-M-15 TEM-1 | ND                |
| 3   | Purulent secretion| AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGC TGY | CTX-M-15 TEM-1 | \textit{tet}(A)  |
| 4   | Purulent secretion| AMK AMP TZP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST IPM MEM MEF TET | CTX-M-15 TEM-1 | ND                |
| 5   | Tracheal aspirate  | AMP CZO CAZ CRB CXM CTX MFX GEN TGB | CTX-M-15 | ND                |
| 6   | Tracheal aspirate  | AMP ATM CZO FEP CAZ CRB CRO CXM CTX GEN TOB TGY ETP | TEM-1 | \textit{tet}(A)  |
| 7   | Catheter           | AMP CZO FEP CAZ CRB CXM CTX CI P MFX NOR TOB TGY IPM | CTX-M-15 TEM-1 | \textit{tet}(A)  |
| 8   | Purulent secretion | AMP ATM CZO FEP CAZ CRB CRO CXM CTX | CTX-M-15 TEM-1 | ND                |
| 9   | Purulent secretion | AMP ATM CZO FEP CAZ CRB CRO CXM CTX | CTX-M-15 TEM-1 | ND                |
| 10  | Purulent secretion | AMK AMP TZP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGC TGY | CTX-M-15 TEM-1 | \textit{tet}(A)  |
| 11  | Purulent secretion | AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGC TGY | CTX-M-15 TEM-1 | ND                |
| 12  | Tracheal aspirate  | AMP ATM CZO FEP CAZ CRB CRO CXM CTX GEN TOB SST TGC TGY | TEM-1 | \textit{tet}(B)  |
| 13  | Tracheal aspirate  | AMP ATM CZO FEP CAZ CRB CRO CXM CTX GEN TOB SST TGC TGY | TEM-1 | ND                |
| 14  | Catheter           | AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR TOB TGY IPM | CTX-M-15 TEM-1 | \textit{tet}(A)  |

### Table 2. Resistance phenotype and associated genotype in the 32 \textit{K. pneumoniae} strains from clinical samples in a Romanian hospital.

| No. | Origin            | Resistance Phenotype | Beta-Lactamases                      | \textit{tet} Genes |
|-----|-------------------|----------------------|--------------------------------------|-------------------|
| 1   | Sputum            | AMK AMP TZP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGC TGY | CTX-M-15 TEM-1 | \textit{tet}(A)  |
| 2   | Sputum            | AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 3   | Pentonial fluid   | AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 4   | Purulent secretion| AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 5   | Pentonial fluid   | AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 6   | Purulent secretion| AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 7   | Purulent secretion| AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 8   | Purulent secretion| AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 9   | Purulent secretion| AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 10  | Purulent secretion| AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 11  | Purulent secretion| AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 12  | Tracheal aspirate  | AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 13  | Tracheal aspirate  | AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |
| 14  | Catheter           | AMP ATM CZO FEP CAZ CRB CRO CXM CTX CI P MFX NOR GEN TOB SST TGY IPM | CTX-M-15 SHV-1 | TEM-1 |

In Romania, there are a few studies on the prevalence of CTXM-15 ESBL variant in isolates from clinical settings [71–73] and in pets [63,74,75].
Regarding the TEM beta-lactamases, in our study, they have been detected in large proportion in E. coli strains (11/14 strains) and K. pneumoniae strains (14/32 strains). Indeed, the \( \text{bla}_{\text{TEM-1}} \) genes were detected more and more frequently in Italian hospitals [81] since new \( \text{tem} \) variants were first detected in K. pneumoniae in France [82] and Korea [83] in 1998.

The prevalence of TEM beta-lactamases was associated with the usage of moxalactam. This drug is not used in Romania, therefore, we suppose that the selective pressure was due to cefotaxime, a commonly used drug. This is supported by the evidence that some TEM beta-lactamases hydrolyse easily the cefotaxime [82].

The TEM- and SHV-type ESBL distribution found in our study was different, overall, from that observed in other countries, confirming a notable variability in the epidemiology of these resistance determinants and underscoring the need to monitor them in different epidemiological settings. It would be interesting to investigate the genetic support and transferability of the various ESBL determinants and the clonal diversity of isolates to understand the role of vector versus clonal spread in the dissemination of these resistance genes.

5. Limitations

One limitation of this study is that we had not known the previous antibiotic treatments in the patients prior to sample collection that could have induced the selection of multidrug-resistant strains.

Another limitation is that we only use primers for specific alleles of the \( \text{bla}_{\text{CTX}}, \text{bla}_{\text{SHV}}, \) and \( \text{bla}_{\text{TEM}} \) genes, but is possible that the studied strains could also harbor other variants of these resistance genes that were not detected by our methodology.

6. Conclusions

This report reveals a high antibiotic resistance in ESBL-producing Enterobacteriaceae circulating in the Oltenia region of Romania and the predominance of the CTXM-15 enzyme among those, especially in E. coli. The SHV enzyme was scarce in E. coli but present in all K. pneumoniae strains, and the TEM enzyme was more frequent in E. coli than in K. pneumoniae. The increased resistance emphasizes the need to implement policies of rationalizing antibiotic use and strengthen the national resistance surveillance system in order to develop local antibiotic therapy guidelines.

Author Contributions: Conceptualization, A.E.G., O.M.C., C.M.V., O.M.Z., M.P. and M.B.; methodology, C.M.V., A.-U. and A.E.G.; software, A.-U., A.E.G., O.M.Z. and A.T.B.; validation, A.E.G., M.B. and O.M.Z.; formal analysis, A.-U., O.M.Z., M.P., D.I., R.R.M. and A.U.; resources, A.-I.S., M.P., A.U. and A.T.B.; data curation, C.M.V., A.T.B. and M.B.; writing—original draft preparation, C.M.V., A.E.G., O.M.C., O.M.Z. and M.B.; writing—review and editing, A.E.G., M.P., O.M.Z., O.M.C., D.I. and R.R.M.; supervision, M.B., A.E.G. and A.T.B. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by internal grant no. 26/36/13 July 2021 “Incidence of Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella strains and prediction of antibiotic resistance profiles using artificial intelligence algorithms” of University of Medicine and Pharmacy of Craiova, Romania. The Article Processing Charges were supported by the University of Medicine and Pharmacy of Craiova, Romania.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of County Clinical Emergency Hospital of Craiova (approval no. 24616/17 June 2021).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Capelo-Martínez, J.L.; Igerejas, G. *Antibiotic Drug Resistance*. John Wiley & Sons: Hoboken, NJ, USA, 2019; pp. 1–692.
2. Carvalho, I.; Silva, N.; Carrola, J.; Silva, V.; Currie, C.; Igerejas, G.; Poeta, P. *Antibiotic Resistance*. John Wiley & Sons: Hoboken, NJ, USA, 2019.
3. Chung, Y.S.; Hu, Y.S.; Shin, S.; Lim, S.K.; Yang, S.J.; Park, Y.H.; Park, K.T. Mechanisms of quinolone resistance in *Escherichia coli* isolated from companion animals, pet-owners, and non-pet-owners. *J. Vet. Sci*. 2017, 18, 449. [CrossRef] [PubMed]
4. Caneiras, C.S.G.; Alises, S.M.; Lito, L.; Cristino, J.M.; Duarte, A. Molecular epidemiology of *Klebsiella pneumoniae*: Multidisciplinary dissemination ofCTX-M-15 extended spectrum β-lactamase. *Eur. Respir. J*. 2018, 52, PA3912.
5. Caneiras, C.; Lito, L.; Melo-Cristino, J.; Duarte, A. Community- and hospital-acquired *Klebsiella pneumoniae* urinary tract infections in Portugal: Virulence and antibiotic resistance. *Microorganisms* 2019, 7, 138. [CrossRef] [PubMed]
6. Carvalho, I.; Chenouf, N.S.; Carvalho, J.A.; Castro, A.P.; Silva, V.; Capita, R.; Alonso-Calleja, C.; de Lurdes Nunes Enes Dapkevicius, M.; Igerejas, G.; Torres, C.; et al. Multidrug-resistant *Klebsiella pneumoniae* harboring extended spectrum β-lactamase encoding genes isolated from human septicemias. *PLoS ONE* 2021, 16, e0250525. [CrossRef]
7. Knothe, H.; Shah, P.; Krkmer, Y.; Antal, M.; Mitsuhashi, S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. *Infection* 1983, 11, 315–317. [CrossRef]
8. Bradford, P.A. Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. *Clin. Microbiol. Rev.* 2001, 14, 933–951. [CrossRef] [PubMed]
9. Bush, K. New beta-lactamases in gram-negative bacteria: Diversity and impact on the selection of antimicrobial therapy. *Clin. Infect. Dis.* 2001, 32, 1085–1089.
10. Coudron, P.E.; Moland, E.S.; Sanders, C.C. Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: Seek and you may find. *J. Clin. Microbiol.* 1997, 35, 2593–2597. [CrossRef]
11. Bush, K.; Fisher, J. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. *Annu. Rev. Microbiol.* 2011, 65, 455–478. [CrossRef]
12. Paterson, D.L.; Bonomo, R.A. Extended-spectrum beta-lactamases: A clinical update. *Clin. Microbiol. Rev.* 2005, 18, 657–686. [CrossRef]
13. Canton, R.; Coque, T.M. The CTX-M beta-lactamase pandemic. *Curr. Opin. Microbiol.* 2006, 9, 466–475. [CrossRef] [PubMed]
14. Ghafourian, S.; Sadeghifard, N.; Soheili, S.; Sekawi, Z. Extended spectrum beta-lactamases: Definition, classification and epidemiology. *Curr. Issues Mol. Biol.* 2015, 17, 11–12. [PubMed]
15. Bonnet, R. Growing group of extended-spectrum beta-lactamases: The CTX-M enzymes. *Antimicrob. Agents Chemother.* 2004, 48, 1–14. [CrossRef] [PubMed]
16. Pokharel, S.; Shrestha, P.; Adhikari, B. Antimicrobial use in food animals and human health: Time to implement ‘One Health’ approach. *Antimicrob. Resist. Infect. Control* 2020, 9, 1–5. [CrossRef]
17. Raut, S.; Adhikari, B. Global leadership against antimicrobial resistance ought to include developing countries. *Lancet. Infect. Dis.* 2016, 16, 775. [CrossRef]
18. Pokharel, S.; Raut, S.; Adhikari, B. Tackling antimicrobial resistance in low-income and middle-income countries. *BMJ Glob. Health* 2019, 4, e002104. [CrossRef]
19. Raya, G.B.; Dhoubbadel, B.G.; Shrestha, D.; Raya, S.; Laghu, U.; Shah, A.; Raya, B.B.; Kafle, R.; Parry, C.M.; Ariyoshi, K. Multidrug-resistant and extended-spectrum beta-lactamase-producing uropathogens in children in Bhaktapur, Nepal. *Trop. Med. Health* 2020, 6, 487. [CrossRef]
20. M100Ed32|Performance Standards for Antimicrobial Susceptibility Testing, 32nd ed.; CLSI: Malvern, PA, USA, 2022; Available online: https://clsi.org/standards/products/microbiology/documents/m100/ (accessed on 1 March 2022).
21. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* 2012, 18, 268–281. [CrossRef]
22. Monstein, H.J.; Östholm-Balkhed, Å.; Nilsson, M.V.; Nilsson, M.; Dornbusch, K.; Nilsson, L.E. Multiplex PCR amplification assay for the detection of blaSHV, blaTEM and blaCTX-M genes in Enterobacteriaceae. *APMIS* 2007, 115, 1400–1408. [CrossRef]
23. Zhang, R.; Huang, Y.; Chan, E.W.C.; Zhou, H.; Chen, S. Dissemination of the mcr-1 colistin resistance gene. *Lancet. Infect. Dis.* 2016, 16, 291–292. [CrossRef]
24. Adelowo, O.O.; Fagade, O.E. The tetracycline resistance gene tet39 is present in both Gram-negative and Gram-positive bacteria from a polluted river, Southwestern Nigeria. *Lett. Appl. Microbiol.* 2009, 48, 167–172. [CrossRef] [PubMed]
25. Denton, M. Enterobacteriaceae. *Int. J. Antimicrob. Agents* 2007, 29 (Suppl. S3), S9–S22. [CrossRef]
26. Obiero, L.; Singh, N.; Sharma, P.; Aggarwal, A. ESBL, MBL and AMPC β-lactamases producing superbugs—Havoc in the intensive care units of Punjab India. *J. Clin. Diagn. Res.* 2013, 7, 70–73. [CrossRef] [PubMed]
27. Cantón, R.; Bryan, J. Global antimicrobial resistance: From surveillance to stewardship. Part 1: Surveillance and risk factors for resistance. *Expert Rev. Anti. Infect. Ther.* 2012, 10, 1269–1271. [CrossRef]
28. Peirano, G.; Pitout, J.D.D. Extended-spectrum β-lactamase-producing Enterobacteriaceae: Update on molecular epidemiology and treatment options. *Drugs* 2019, 79, 1529–1541. [CrossRef]
29. Jean, S.S.; Hsueh, P.R. High burden of antimicrobial resistance in Asia. *Int. J. Antimicrob. Agents* 2011, 37, 291–295. [CrossRef]
30. Bonelli, R.R.; Moreira, B.M.; Picão, R.C. Antimicrobial resistance among Enterobacteriaceae in South America: History, current dissemination status and associated socioeconomic factors. *Drug Resist. Update*. 2014, 17, 24–36. [CrossRef]

31. Leopold, S.J.; van Leth, F.; Tarekegn, H.; Schultz, C. Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: A systematic review. *J. Antimicrob. Chemother.* 2014, 69, 2337–2353. [CrossRef]

32. Sonda, T.; Kumburu, H.; van Zwetselaar, M.; Alfrangis, M.; Lund, O.; Kibiki, G.; Aarestrup, F.M. Meta-analysis of proportion estimates of Extended-Spectrum-Beta-Lactamase-producing Enterobacteriaceae in East Africa hospitals. *Antimicrob. Resist. Infect. Control* 2016, 5, 1–9. [CrossRef]

33. Chong, Y.; Shimoda, S.; Shimono, N. Current epidemiology, genetic evolution and clinical impact of extended-spectrum β-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*. * Infect. Genet. Evol.* 2018, 61, 185–188. [CrossRef]

34. Rus, M.; Licker, M.; Musuroi, C.; Seclaman, E.; Muntean, D.; Cirlea, N.; Tamas, A.; Vulpie, S.; Horhat, F.G.; Baditoiu, L. Distribution of NDM1 carbapenemase-producing proteeae strains on high-risk hospital wards. * Infect. Drug Resist.* 2020, 13, 4791–4761. [CrossRef] [PubMed]

35. Axente, C.; Licker, M.; Moldovan, R.; Hogeia, E.; Muntean, D.; Horhat, F.; Bedreag, O.; Sandesc, D.; Papurica, M.; Dugaesescu, D.; et al. Antimicrobial consumption, costs and resistance patterns: A two year prospective study in a Romanian intensive care unit. *BMC Infect. Dis.* 2017, 17, 1–9. [CrossRef] [PubMed]

36. Cristea, O.M.; Zlatian, O.M.; Dinescu, S.N.; Bâlășoiu, A.T.; Avramescu, C.; Bâlășoiu, M.; Niculescu, M.; Calina, D. A Comparative Study on Antibiotic Resistance of Klebsiella Strains from Surgical and Intensive Care Wards. *Curr. Health Sci. J.* 2016, 42, 169–179. [CrossRef]

37. Ghenea, A.E.; Cioboatu, R.; Drocăș, A.I.; Tieranu, E.N.; Vasile, C.M.; Moroșanu, A.; Tieranu, C.G.; Salan, A.-I.; Popescu, M.; Turculeanu, A.; et al. Prevalence and antimicrobial resistance of *Klebsiella* strains isolated from a county hospital in Romania. *Antibiotics* 2021, 10, 868. [CrossRef]

38. Bradford, P.A.; Cherubin, C.E.; Idemiyor, V.; Rasmussen, B.A.; Bush, K. Multiply resistant *Klebsiella pneumoniae* strains from two Chicago hospitals: Identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate. *Antimicrob. Agents Chemother.* 1994, 38, 761–766. [CrossRef] [PubMed]

39. De Champs, C.; Sirot, D.; Chanal, C.; Poupart, M.C.; Dumas, M.P.; Sirot, J. Concomitant dissemination of three extended-spectrum beta-lactamases among different Enterobacteriaceae isolated in a French hospital. *J. Antimicrob. Chemother.* 1991, 27, 441–457. [CrossRef] [PubMed]

40. Kim, J.; Kwon, Y.; Pai, H.; Kim, J.W.; Cho, D.T. Survey of *Klebsiella pneumoniae* strains producing extended-spectrum beta-lactamases: Prevalence of SHV-12 and SHV-2a in Korea. *J. Clin. Microbiol.* 1998, 36, 1446–1449. [CrossRef]

41. Paluchka, A.; Mikiewicz, B.; Hryniewicz, W.; Gniadkowski, M. Concurrent outbreaks of extended-spectrum beta-lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospital. *J. Antimicrob. Chemother.* 1999, 44, 489–499. [CrossRef] [PubMed]

42. Rosenthal, V.D.; Duszynska, W.; Ider, B.E.; Gurskis, V.; Al-Ruzzieh, M.A.; Myatra, S.N.; Gupta, D.; Belkebir, S.; Upadhyay, N.; Zand, F.; et al. International nosocomial infection control consortium (INICC) report, data summary of 45 countries for 2013–2018, adult and pediatric units, device-associated module. *Am. J. Infect. Control* 2021, 49, 1267–1274. [CrossRef]

43. Rodloff, A.C.; Goldstein, E.J.C.; Torres, A. Two decades of imipenem therapy. *J. Antimicrob. Chemother.* 2006, 58, 916–929. [CrossRef]

44. Wu, M.J.; Feng, Y.S.; Sung, W.P.; Surampalli, R.Y. Quantification and analysis of airborne bacterial characteristics in a nursing care institution. *J. Air Waste Manag. Assoc.* 2007, 96, 732–739. [CrossRef] [PubMed]

45. Van Almsick, V.P.; Schuler, F.; Mellmann, A.; Schwierzeck, V. The use of long-read sequencing technologies in infection control: Horizontal transfer of a *blaCTX-M-27* containing IncFII plasmid in a patient screening sample. *Microorganisms* 2022, 10, 491. [CrossRef] [PubMed]

46. Vubil, D.; Figueiredo, R.; Reis, T.; Canha, C.; Boaventura, L.; Da Silva, G.J. Outbreak of KPC-3-producing ST15 and ST348 *Klebsiella pneumoniae* in a Portuguese hospital. *Epidemiol. Infect.* 2017, 145, 595–599. [CrossRef] [PubMed]

47. Schauffer, K.; Semmler, T.; Wieler, L.H.; Wöhrmann, M.; Baddam, R.; Ahmed, N.; Müller, K.; Kola, A.; Fruth, A.; Ewers, C.; et al. Clonal spread and interspecies transmission of clinically relevant ESBL-producing *Escherichia coli* of ST410—Another successful pandemic clone? *FEMS Microbiol. Ecol.* 2016, 92, fiv155. [CrossRef]

48. Louka, C.; Ravensbergen, S.J.; Ott, A.; Zhou, X.; Garcia-Cobos, S.; Friedrich, A.W.; Pournaras, S.; Rosema, S.; Rossen, J.W.; Stienstra, Y.; et al. Predominance of CTX-M-15-producing ST131 strains among ESBL-producing *Escherichia coli* isolated from asylum seekers in the Netherlands. *J. Antimicrob. Chemother.* 2021, 76, 70–76. [CrossRef]

49. Licker, M.; Baditoiu, L.; Muntean, D.; Dragomirescu, L.; Horhat, F.; Piluţ, C.; Hogeia, E.; Deutsch, P.; Adam, A.; Moldovan, R. Surveillance of multi-drug resistant pathogens in two Romanian university hospitals. *Int. J. Infect. Control* 2012, 8, 4. [CrossRef]

50. Poulou, A.; Grivakou, E.; Vrioni, G.; Kounaki, V.; Pittaras, T.; Pournaras, S.; Tsakris, A. Modified CLSI Extended-Spectrum β-Lactamase (ESBL) Confirmatory Test for Phenotypic Detection of ESBLs among Enterobacteriaceae Producing Various β-Lactamases. *J. Clin. Microbiol.* 2014, 52, 1483. [CrossRef]

51. Hanberger, H.; Edlund, C.; Furebring, M.; Giske, C.G.; Melhus, Å.; Nilsson, L.E.; Petersson, J.; Sjölin, J.; Ternhag, A.; Werner, M.; et al. Rational use of aminoglycosides—Review and recommendations by the Swedish reference group for antibiotics (SRGA). *Scand. J. Infect. Dis.* 2013, 45, 161–175. [CrossRef]
52. Leibovici, L.; Vidal, L.; Paul, M. Aminoglycoside drugs in clinical practice: An evidence-based approach. *J. Antimicrob. Chemother.* 2009, 63, 246–251. [CrossRef]
53. Cho, S.Y.; Choi, S.M.; Park, S.H.; Lee, D.G.; Choi, J.H.; Yoo, J.H. Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing *Escherichia coli*. *Korean J. Intern. Med.* 2016, 31, 156. [CrossRef]
54. Yang, Y.; Bhachech, N.; Bradford, P.A.; Jett, B.D.; Sahn, D.F.; Bush, K. Ceftazidime-resistant *Klebsiella pneumoniae* and *Escherichia coli* isolates producing TEM-10 and TEM-43 beta-lactamases from St. Louis, Missouri. *Antimicrob. Agents Chemother.* 1998, 42, 1671–1676. [CrossRef]
55. Castanheira, M.; Simner, P.J.; Bradford, P.A. Extended-spectrum β-lactamases: An update on their characteristics, epidemiology and detection. *JAC-Antimicrob. Resist.* 2021, 3, dlab092. [CrossRef] [PubMed]
56. Rocha, F.R.; Pinto, V.P.T.; Barbosa, F.C.B. The spread of CTX-M-type extended-spectrum β-lactamases in Brazil: A systematic review. *Microb. Drug Resist.* 2016, 22, 301–311. [PubMed]
57. Mendonça, N.; Leitão, J.; Manageiro, V.; Ferreira, E.; Caniça, M. Spread of extended-spectrum β-lactamide CTX-M-producing *Escherichia coli* clinical isolates in community and nosocomial environments in Portugal. *Antimicrob. Agents Chemother.* 2007, 51, 1946–1955. [PubMed]
58. Kirtikliene, T.; Mierauskaite, A.; Razmienė, I.; Kusiene, N. Genetic characterization of multidrug-resistant *E. coli* isolates from bloodstream infections in Lithuania. *Microorganisms* 2022, 10, 449. [CrossRef] [PubMed]
59. Melegh, S.; Schneider, G.; Horváth, M.; Jakab, E.; Emödy, L.; Tigyi, Z. Identification and characterization of CTX-M-15 producing *Klebsiella pneumoniae* clone ST101 in a Hungarian university teaching hospital. *Acta Microbiol. Immunol. Hung.* 2015, 62, 233–234. [CrossRef] [PubMed]
60. Schmiedel, J.; Falgenhauer, L.; Domann, E.; Bauerfeind, R.; Prenger-Berninghoff, E.; Imirzalioglu, C.; Chakraborty, T. Multiresistant extended-spectrum β-lactamase-producing *Enterobacteriaceae* from humans, companion animals and horses in central Hesse, Germany. *BMC Microbiol.* 2014, 14, 1–13. [CrossRef]
61. Silva, M.M.; Fernandes, M.R.; Sellera, F.P.; Cerdeira, L.; Medeiros, L.K.G.; Garino, F.; Azvedo, S.S.; Linçopan, N. Multidrug-resistant CTX-M-15-producing *Klebsiella pneumoniae* ST231 associated with infection and persistent colonization of dog. *Diagn. Microbiol. Infect. Dis.* 2018, 92, 259–261. [PubMed]
62. Carvalho, I.; Cunha, R.; Martins, C.; Martinez-Alvarez, S.; Chenouf, N.S.; Pimenta, P.; Pereira, A.R.; Ramos, S.; Sadi, M.; Martins, A.; et al. Antimicrobial resistance genes and diversity of clones among *FAECAL ESBL*-producing *Escherichia coli* isolated from healthy and sick dogs living in Portugal. *Antibiotics* 2021, 10, 1013. [CrossRef]
63. Maciuca, I.E.; Williams, N.J.; Tuchilus, C.; Dorneanu, O.; Guguianu, E.; Carp-Carare, C.; Rimbu, C.; Timofto, D. High prevalence of *Escherichia coli*-producing CTX-M-15 extended-spectrum beta-lactamases in poultry and human clinical isolates in Romania. *Microb. Drug Resist.* 2015, 21, 651–662. [CrossRef]
64. Rodriguez-Navarro, F.; Miró, E.; Brown-Jaque, M.; Hurtado, J.C.; Moreno, A.; Muniesa, M.; González-López, J.J.; Vila, J.; Espinal, P.; Navarro, F. Comparison of commensal and clinical isolates for diversity of plasmids in *Escherichia coli* and *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 2020, 64, e02064–19. [CrossRef] [PubMed]
65. Belas, A.; Marques, C.; Aboim, C.; Pomba, C. Emergence of *Escherichia coli* ST131 H30/H30-Rx subclones in companion animals. *J. Antimicrob. Chemother.* 2019, 74, 266–269. [CrossRef] [PubMed]
66. Nicolas-Chanoine, M.H.; Blanco, J.; Leflon-Guibout, V.; Demarty, R.; Alonso, M.P.; Caniça, M.M.; Park, Y.J.; Lavigne, J.P.; Pitout, J.; Johnson, J.R. Intercontinental emergence of *Escherichia coli* clone O25:H4-ST131 producing CTX-M-15. *J. Antimicrob. Chemother.* 2008, 61, 273–281. [CrossRef]
67. Yones, A.; Hamouda, A.; Dave, J.; Amyes, S.G.B. Prevalence of transferable blaCTX-M-15 from hospital- and community-acquired *Klebsiella pneumoniae* isolates in Scotland. *J. Antimicrob. Chemother.* 2011, 66, 313–318. [CrossRef] [PubMed]
68. Xercavins, M.; Jiménez, E.; Padilla, E.; Riera, M.; Freixas, N.; Boix-Palop, L.; Pérez, J.; Calbo, E. High clonal diversity of ESBL-producing *Klebsiella pneumoniae* clinical isolates from clinical samples in a non-outbreak situation. A cohort study. *Antimicrob. Resist. Infect. Control* 2020, 9, 1–9. [CrossRef] [PubMed]
69. Haenni, M.; Ponsin, C.; Métayer, V.; Médaillé, C.; Madec, J.Y. Veterinary hospital-acquired infections in pets with a ciprofloxacin-resistant CTX-M-15-producing *Escherichia coli* ST15 clone. *J. Antimicrob. Chemother.* 2012, 67, 770–771. [CrossRef] [PubMed]
70. Donati, V.; Feltrin, F.; Hendrikse, R.S.; Svendsen, C.A.; Cordaro, G.; García-Fernández, A.; Lorenzetti, S.; Lorenzetti, R.; Battisti, A.; Franco, A. Extended-spectrum-beta-lactamases, AmpC beta-lactamases and plasmid-mediated quinolone resistance in *klebsiella* spp. from companion animals in Italy. *PLoS ONE* 2014, 9, e90564. [CrossRef]
71. Usein, C.R.; Papageorghe, R.; Oprea, M.; Condei, M.; Străuş, M. Molecular characterization of bacteremic *Escherichia coli* isolates in Romania. *Folia Microbiol.* 2016, 61, 221–226. [CrossRef]
72. Mirotide, E.; Dormeau, O.; Badasco, A.; Ghibu, I.; Leca, D.; Vremera, T.; Mereuţă, A. Emergence of a new group CTX-M enzyme in Romania and risk factors for extended spectrum beta-lactamase producing *E. coli* infections. *Rev. Med.-Chir. A Soc. Med. Si Nat. Din Iasi* 2012, 116, 477–480.
73. Popa, L.I.; Gheorghe, I.; Barbu, I.C.; Surlac, M.; Paraschiv, S.; Mărăuşcu, L.; Popa, M.; Pircălăbioru, G.G.; Talapan, D.; Nîţă, M.; et al. Multidrug Resistant *Klebsiella pneumoniae* ST101 clone survival chain from inpatients to hospital effluent after chlorane treatment. *Front. Microbiol.* 2021, 11, 3403. [CrossRef]
74. Timofte, D.; Maciuca, I.E.; Williams, N.J.; Wattret, A.; Schmidt, V. Veterinary hospital dissemination of CTX-M-15 extended-spectrum beta-lactamase-producing *Escherichia coli* ST410 in the United Kingdom. *Microb. Drug Resist.* 2016, 22, 609–615. [CrossRef] [PubMed]
75. Shnaiderman-Torban, A.; Navon-Venezia, S.; Dahan, R.; Dor, Z.; Taulescu, M.; Paitan, Y.; Edery, N.; Steinman, A. CTX-M-15 producing *Escherichia coli* sequence type 361 and sequence type 38 causing bacteremia and umbilical infection in a neonate foal. *J. Equine Vet. Sci.* 2020, 85, 102881. [CrossRef] [PubMed]
76. Lamoureux, T.L.; Frase, H.; Antunes, N.T.; Vakulenko, S.B. Antibiotic resistance and substrate profiles of the class a carbapenemase KPC-6. *Antimicrob. Agents Chemother.* 2012, 56, 6006–6008. [CrossRef] [PubMed]
77. Wysocka, M.; Zamudio, R.; Oggioni, M.R.; Gołębiowska, J.; Bronk, M.; Krawczyk, B. Genetic background and antibiotic resistance profiles of *K. pneumoniae* NDM-1 strains isolated from Uti, Abu, and the Gi tract, from one hospital in Poland, in Relation to strains nationally and worldwide. *Genes* 2021, 12, 1285. [CrossRef]
78. Alcalá, L.; Alonso, C.A.; Simón, C.; Gonzalez-Esteban, C.; Orós, J.; Rezusta, A.; Ortega, C.; Torres, C. Wild Birds, Frequent carriers of extended-spectrum β-lactamase (ESBL) producing *Escherichia coli* of CTX-M and SHV-12 types. *Microb. Ecol.* 2016, 72, 861–869. [CrossRef]
79. Veldman, K.; van Tulden, P.; Kant, A.; Testerink, J.; Mevius, D. Characteristics of cefotaxime-resistant *Escherichia coli* from wild birds in The Netherlands. *Appl. Environ. Microbiol.* 2013, 79, 7556–7561. [CrossRef]
80. Liakopoulos, A.; Mevius, D.; Ceccarelli, D. A review of SHV extended-spectrum β-lactamas: Neglected yet ubiquitous. *Front. Microbiol.* 2016, 7, 1374. [CrossRef]
81. Perilli, M.; Dell’Amico, E.; Segatore, B.; De Massis, M.R.; Bianchi, C.; Luzzaro, F.; Rossolini, G.M.; Toniolo, A.; Nicoletti, G.; Amicosante, G. Molecular characterization of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. *J. Clin. Microbiol.* 2002, 40, 611–614. [CrossRef]
82. Poyart, C.; Mugnier, P.; Quesne, G.; Berche, P.; Trieu-Cuot, P. A novel extended-spectrum TEM-type beta-lactamase (TEM-52) associated with decreased susceptibility to moxalactam in *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 1998, 42, 108–113. [CrossRef]
83. Pai, H.; Lyu, S.; Lee, J.H.; Kim, J.; Kwon, Y.; Kim, J.W.; Choe, K.W. Survey of extended-spectrum beta-lactamases in clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae*: Prevalence of TEM-52 in Korea. *J. Clin. Microbiol.* 1999, 37, 1758–1763. [CrossRef]